MDGL icon

Madrigal Pharmaceuticals

333.91 USD
-6.89
2.02%
At close Apr 30, 4:00 PM EDT
After hours
339.98
+6.07
1.82%
1 day
-2.02%
5 days
8.00%
1 month
0.81%
3 months
-1.29%
6 months
54.64%
Year to date
6.42%
1 year
63.67%
5 years
299.03%
10 years
324.01%
 

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

86% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 36

49% more capital invested

Capital invested by funds: $4.76B [Q3] → $7.08B (+$2.32B) [Q4]

22% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 76

11% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 10 (+1) [Q4]

10% more call options, than puts

Call options by funds: $354M | Put options by funds: $321M

10% more funds holding

Funds holding: 254 [Q3] → 280 (+26) [Q4]

1.13% more ownership

Funds ownership: 104.09% [Q3] → 105.22% (+1.13%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$405
21%
upside
Avg. target
$439
31%
upside
High target
$469
40%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
JMP Securities
Jonathan Wolleben
49% 1-year accuracy
33 / 68 met price target
33%upside
$443
Market Outperform
Reiterated
24 Apr 2025
Citigroup
David Lebovitz
63% 1-year accuracy
10 / 16 met price target
40%upside
$469
Buy
Maintained
27 Feb 2025
HC Wainwright & Co.
Ed Arce
40% 1-year accuracy
61 / 151 met price target
21%upside
$405
Buy
Maintained
27 Feb 2025

Financial journalist opinion

Based on 3 articles about MDGL published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands.
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
Neutral
GlobeNewsWire
1 week ago
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets.
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
Neutral
GlobeNewsWire
2 weeks ago
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.
Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.
Positive
Zacks Investment Research
1 month ago
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?
Neutral
GlobeNewsWire
1 month ago
Madrigal Appoints Jacqualyn A. Fouse, Ph.D.
Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa.
Madrigal Appoints Jacqualyn A. Fouse, Ph.D.
Positive
Seeking Alpha
2 months ago
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's Phase 3 trial aims to expand Rezdiffra's label to early cirrhosis by 2027, with EMA approval expected in mid-2025. GLP-1s like semaglutide and tirzepatide show promising MASH results, potentially disrupting Rezdiffra's market despite its first-mover advantage.
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Positive
Zacks Investment Research
2 months ago
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Positive
Benzinga
2 months ago
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Positive
Seeking Alpha
2 months ago
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target.
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Positive
The Motley Fool
2 months ago
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday.
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Charts implemented using Lightweight Charts™